A PHASE-I TRIAL OF TRIMETREXATE GLUCURONATE (NSC-352122) GIVEN EVERY 3 WEEKS - CLINICAL-PHARMACOLOGY AND PHARMACODYNAMICS

被引：23

作者：

GROCHOW, LB

NOE, DA

ETTINGER, DS

DONEHOWER, RC

机构：

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1989年 / 24卷 / 05期

关键词：

D O I：

10.1007/BF00304765

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：314 / 320

页数：7

共 27 条

[1]

BALIS FM, 1986, CANCER RES, V46, P169

[2] 2,4-DIAMINO-5-METHYL-6-[(3,4,5-TRIMETHOXYANILINO)METHYL]QUINAZOLINE (TMQ), A POTENT NON-CLASSICAL FOLATE ANTAGONIST INHIBITOR .1. EFFECT ON DIHYDROFOLATE-REDUCTASE AND GROWTH OF RODENT TUMORS INVITRO AND INVIVO [J].

BERTINO, JR ;

SAWICKI, WL ;

MOROSON, BA ;

CASHMORE, AR ;

ELSLAGER, EF .

BIOCHEMICAL PHARMACOLOGY, 1979, 28 (12) :1983-1987

[3]

BERTINO JR, 1987, NATL CANCER I MONOGR, V5, P87

[4]

CHABNER B, 1982, PHARM PRINCIPLES CAN, P236

[5]

DIDDENS H, 1983, CANCER RES, V43, P5286

[6]

DRAKE JC, 1985, CANCER TREAT REP, V69, P641

[7] TRIMETREXATE - PREDICTORS OF SEVERE OR LIFE-THREATENING TOXIC EFFECTS [J].

EISENHAUER, EA ;

ZEE, BC ;

PATER, JL ;

WALSH, WR .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (16) :1318-1322

[8]

FANUCCHI MP, 1987, CANCER RES, V47, P3303

[9]

FRY DW, 1986, CANCER SURV, V5, P47

[10]

Gibaldi M., 1982, PHARMACOKINETICS, P445

← 1 2 3 →